Literature DB >> 7055689

Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia.

M Ruberg, A Ploska, F Javoy-Agid, Y Agid.   

Abstract

[3H]Quinuclidinylbenzilate ([3H]QNB) binding and choline acetyltransferase (CAT) activity were studied in post-mortem brains from control and Parkinsonian subjects. CAT levels were reduced in the cortex and hippocampus of Parkinsonians. The apparent affinity of [3H]QNB for the muscarinic receptor was higher in both the caudate nucleus and the frontal cortex. Receptor density increased only in the frontal cortex. These changes are discussed in relation to dementia and mental disturbances following anticholinergic treatment frequently observed in Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7055689     DOI： 10.1016/0006-8993(82)90615-1

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  32 in total

1.  Cortical nicotinic receptors in Alzheimer's disease and Parkinson's disease.

Authors:  K W Lange; F R Wells; M N Rossor; P Jenner; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

2.  Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.

Authors:  B Ravina; M Putt; A Siderowf; J T Farrar; M Gillespie; A Crawley; H H Fernandez; M M Trieschmann; S Reichwein; T Simuni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

3.  MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia.

Authors:  Haruo Hanyu; Tetsuichi Asano; Hirofumi Sakurai; Yuriko Tanaka; Masaru Takasaki; Kimihiko Abe
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

Review 4.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

5.  Cholinergic cortical circuits in Parkinson's disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study.

Authors:  Raffaele Nardone; Igor Florio; Piergiorgio Lochner; Frediano Tezzon
Journal:  Exp Brain Res       Date:  2005-03-08       Impact factor: 1.972

6.  Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.

Authors:  M Asahina; T Suhara; H Shinotoh; O Inoue; K Suzuki; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

Review 7.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

8.  Acetylcholine synthesis in human CSF: implications for study of central cholinergic metabolism.

Authors:  S T DeKosky; S W Scheff; C G Hackney
Journal:  Neurochem Res       Date:  1989-02       Impact factor: 3.996

9.  Confusion, dementia and anticholinergics in Parkinson's disease.

Authors:  Y de Smet; M Ruberg; M Serdaru; B Dubois; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

10.  Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy.

Authors:  E C Hirsch; A M Graybiel; C Duyckaerts; F Javoy-Agid
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.